Omalizumab Use in Chronic Spontaneous Urticaria during Pregnancy and a Four Years' Follow-Up: A Case Report
Chronic spontaneous urticaria (CSU) is a benign skin disorder usually responsive to treatment; however, at times it can be difficult to control and become very debilitating. We discuss the case of a woman with CSU that was unresponsive to H1-antihistamines who was treated with omalizumab and became...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
Karger Publishers,
2020-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_183f5d93e8a646dbbcb3e21f1e7076a9 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Laura Michelina Losappio |e author |
| 700 | 1 | 0 | |a Corrado Mirone |e author |
| 700 | 1 | 0 | |a Jan Walter Schroeder |e author |
| 700 | 1 | 0 | |a Joseph Scibilia |e author |
| 700 | 1 | 0 | |a Luca Balossi |e author |
| 700 | 1 | 0 | |a Elide Anna Pastorello |e author |
| 245 | 0 | 0 | |a Omalizumab Use in Chronic Spontaneous Urticaria during Pregnancy and a Four Years' Follow-Up: A Case Report |
| 260 | |b Karger Publishers, |c 2020-10-01T00:00:00Z. | ||
| 500 | |a 1662-6567 | ||
| 500 | |a 10.1159/000509179 | ||
| 520 | |a Chronic spontaneous urticaria (CSU) is a benign skin disorder usually responsive to treatment; however, at times it can be difficult to control and become very debilitating. We discuss the case of a woman with CSU that was unresponsive to H1-antihistamines who was treated with omalizumab and became pregnant during omalizumab treatment. We also considered the follow-up of the mother and newborn for 4 years after delivery. Our case report confirms that omalizumab is a safe and effective therapeutic option, after careful evaluations in terms of cost-effectiveness, in pregnant and lactating women with severe chronic urticaria. Assessment throughout follow-up confirmed a regular progression of pregnancy parameters and no adverse reaction was documented in the child from birth to 4 years of age. | ||
| 546 | |a EN | ||
| 690 | |a urticaria | ||
| 690 | |a pregnancy | ||
| 690 | |a omalizumab | ||
| 690 | |a Dermatology | ||
| 690 | |a RL1-803 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Case Reports in Dermatology, Vol 12, Iss 3, Pp 174-177 (2020) | |
| 787 | 0 | |n https://www.karger.com/Article/FullText/509179 | |
| 787 | 0 | |n https://doaj.org/toc/1662-6567 | |
| 856 | 4 | 1 | |u https://doaj.org/article/183f5d93e8a646dbbcb3e21f1e7076a9 |z Connect to this object online. |